Kei Muro

Active 1997–2025

178
Papers
38,056
Citations
81
h-index
170
i10-index

Citations

Citations per year for Kei Muro1991: 3 citations1995: 1 citations1997: 6 citations1999: 3 citations2000: 5 citations2001: 6 citations2002: 19 citations2003: 21 citations2004: 26 citations2005: 33 citations2006: 35 citations2007: 36 citations2008: 39 citations2009: 50 citations2010: 40 citations2011: 35 citations2012: 69 citations2013: 74 citations2014: 130 citations2015: 164 citations2016: 163 citations2017: 300 citations2018: 349 citations2019: 1,532 citations2020: 2,132 citations2021: 2,002 citations2022: 1,539 citations2023: 1,090 citations2024: 1,743 citations2025: 767 citations2026: 24 citations1992–1994: no citations, so these years are not shown1996: no citations, so this year is not shown1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 2,335 citing papers, 17.8% of this breakdownUnited States: 2,200 citing papers, 16.8% of this breakdownJapan: 1,710 citing papers, 13% of this breakdownItaly: 772 citing papers, 5.9% of this breakdownUnited Kingdom: 589 citing papers, 4.5% of this breakdownGermany: 549 citing papers, 4.2% of this breakdownFrance: 470 citing papers, 3.6% of this breakdownSouth Korea: 444 citing papers, 3.4% of this breakdownSpain: 400 citing papers, 3% of this breakdownNetherlands: 338 citing papers, 2.6% of this breakdownCanada: 253 citing papers, 1.9% of this breakdownBelgium: 218 citing papers, 1.7% of this breakdown
0%17.8%Other 21.6%

Fields

  • Medicine75.4%
  • Biochemistry, Genetics and Molecular Biology14.4%
  • Materials Science3.5%
  • Immunology and Microbiology3.4%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Neuroscience0.7%
  • Other1.7%

Topics

  • Cancer Immunotherapy and Biomarkers9.9%
  • Gastric Cancer Management and Outcomes7%
  • Colorectal Cancer Treatments and Studies6.2%
  • Esophageal Cancer Research and Treatment4.4%
  • Colorectal Cancer Surgical Treatments3.3%
  • Genetic factors in colorectal cancer2.4%
  • Other66.8%

Coauthors

All papers

Open in search
  1. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2017 cited by 2,279

  2. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 cited by 1,812

  3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 cited by 3,449

  4. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hiroyuki Uetake, Shigeki Yamaguchi, Naohiko YAMAGUCHI, Hirotoshi Kobayashi, Keiji Matsuda, Kenjiro Kotake, Kenichi Sugihara, Japanese Society for Cancer of the Colon and Rectum - International Journal of Clinical Oncology 2019 cited by 1,958

  5. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 1,176

  6. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2014 cited by 2,471

  7. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Genichi Nishimura, Yuh Sakata, Yasuhiro Shimada, Keiichi Takahashi, Shinji Tanaka, Osamu Tsuruta, Toshiharu Yamaguchi, Naohiko YAMAGUCHI, Toshiaki Tanaka, Kenjiro Kotake, Kenichi Sugihara - International Journal of Clinical Oncology 2017 cited by 2,490

  8. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean–Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Müller, Felipe Rey, Ángela R. Zambrano, Joaquín Guerra, Merete Krogh, Lene Bæksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Päivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Eray Goekkurt, Thomas Hoehler, Georg Martin Haag, Salah‐Eddin Al‐Batran, Hugo R. Castro, Karla Alejandra Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinéad Cuffe, Cathy Kelly, Ravit Geva, Einat Shacham‐Shmueli, Ayala Hubert, Alex Beny, Baruch Brenner, Giuseppe Aprile, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chìn, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernández Hernández, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Olav Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Z. Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay and 58 more - The Lancet 2018 cited by 1,316

  9. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

    Authors: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 cited by 443

  10. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 288

  11. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2023 cited by 258

  12. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 583

  13. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

    Authors: , , , , , , , , , , , , , , , , , , , - British Journal of Cancer 2018 cited by 456

  14. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 1,131

  15. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric Van Cutsem - ESMO Open 2023 cited by 161

  16. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 859

  17. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2017 cited by 592

  18. LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 82

  19. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 197

  20. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

    Authors: , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2021 cited by 166

  21. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

    Authors: , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 152

  22. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takayuki Yoshino - Nature Medicine 2024 cited by 110

  23. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

    Authors: , , , , , , , , , , , - Future Oncology 2022 cited by 133

  24. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Gastric Cancer 2019 cited by 231